secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-012263
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024
--------------------------------------------------------------------------------

- FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
- Q4 revenue $87.0M (+1%); core reports +42%. TissueCypher reports up 86% in FY2025.
- Net loss $24.2M ($0.83 loss per share) vs net income $18.2M ($0.66 EPS) in 2024. Adj. net loss per share $0.14.
- Adjusted EBITDA $44.0M (FY2025) vs $75.0M (2024); net cash from ops $64.3M; cash & securities $299.5M at year-end.
- 2026 revenue guidance $340-350M; AdvanceAD-Tx limited launch; multiple publications support test utility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026012263/0001628280-26-012263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026012263/cstl-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-012263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer